Autopsy report · NCT04492436

A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo

“Study design was changed”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Veloxis Pharmaceuticals

Sponsor type

Industry

Conditions

Chemotherapy-induced Peripheral Neuropathy

Interventions

thrombomodulin alfa; Placebo

Participants

0

Trials that died the same way

• A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
  “Decision to change the study design” (88% match in meaning)
• Effectiveness and Tolerability of LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses
  “New study design will be made” (84% match in meaning)
• Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.
  “Study design will be reformulated” (83% match in meaning)
• LEGION™ Revision Metal Hypersensitivity Study
  “Overhaul of Study Design” (80% match in meaning)
• Wellness Engagement Project, Petersburg
  “Study Design was changed - no longer prospectively assigning participants” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.